Results 101 to 110 of about 37,814 (299)

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

JAMA ophthalmology, 2019
This randomized clinical trial compares the clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for the management of macular edema secondary to central retinal vein occlusion.
P. Hykin, A. T. Prevost, Joana C Vasconcelos, C. Murphy, J. Kelly, J. Ramu, B. Hounsome, Yit C. Yang, S. Harding, A. Lotery, U. Chakravarthy, S. Sivaprasad   +11 more
semanticscholar   +1 more source

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)—A non‐inferiority, randomized controlled trial

Acta Ophthalmologica, EarlyView.
Abstract Purpose This trial evaluated the noninferiority of a relaxed compared to a strict treat‐and‐extend treatment strategy in patients with neovascular Age‐related macular degeneration (AMD). Methods Multicenter, randomized, controlled, phase IV, non‐inferiority clinical trial.
Damian Jaggi, Lieselotte E. Berger, Sandrine Zweifel, Matthias D. Becker, Stephan Michels, Odile Stalder, Joel‐Benjamin Lincke, Oussama Habra, Sebastian Wolf, Martin S. Zinkernagel   +9 more
wiley   +1 more source

Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up [PDF]

, 2013
PURPOSE: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice.
Faria de Abreu, JR, Figueira, J, Fonseca, P, Luz Cachulo, M, Marques, I, Pires, I, Silva, R   +6 more
core   +1 more source

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration

Journal of International Medical Research, 2020
Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.
Hai-Tao Pan, Jun-Jun Wang, Jun-Long Huang, Yuan-Lu Shuai, Jia Li, Zi-Zhong Hu, Yu-Zhi Ding, Qing-Huai Liu   +7 more
doaj   +1 more source

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Retina, 2017
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). Methods: Prospective,
R. Avery, A. Castellarin, N. Steinle, D. Dhoot, D. Pieramici, R. See, Steven C. Couvillion, M. Nasir, M. Rabena, M. Maia, Sherri A Van Everen, K. Le, W. Hanley   +12 more
semanticscholar   +1 more source

Ranibizumab for the treatment of degenerative ocular conditions

Clinical Ophthalmology, 2014
Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these ...
Triantafylla, Magdalini, Massa, Horace, Dardabounis, Doukas, Gatzioufas, Zisis, Kozobolis, Vassilios, Ioannakis, Konstantinos, Perente, Irfan, Panos, Georgios   +7 more
openaire   +7 more sources

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy [PDF]

Scientific Reports, 2019
AbstractThis retrospective study was to compare the efficacy of intravitreal injection of ranibizumab and aflibercept for patients with pachychoroid neovasculopathy. 54 eyes were initially treated with 3 monthly loading injections of ranibizumab or aflibercept. Treatment switching from ranibizumab to aflibercept, and aflibercept to photodynamic therapy
Byung Ju Jung, Joo Young Kim, Jae Hyung Lee, Jiwon Baek, Kook Lee, Won Ki Lee   +5 more
openaire   +3 more sources

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

Predicting optical coherence tomography-derived diabetic macular edema grades from fundus photographs using deep learning

, 2019
Diabetic eye disease is one of the fastest growing causes of preventable blindness. With the advent of anti-VEGF (vascular endothelial growth factor) therapies, it has become increasingly important to detect center-involved diabetic macular edema (ci-DME)
Bavishi, Pinal, Bresnick, George, Chotcomwongse, Peranut, Corrado, Greg S, Cuadros, Jorge, Kanai, Kuniyoshi, Keane, Pearse A, Ledsam, Joe, Limwattanayingyong, Jirawut, Narayanaswamy, Arunachalam, Nganthavee, Variya, Peng, Lily, Raumviboonsuk, Paisan, Silpa-archa, Sukhum, Tadarati, Mongkol, Varadarajan, Avinash, Venugopalan, Subhashini, Webster, Dale R   +17 more
core   +1 more source

The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema [PDF]

, 2016
Aims: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database.
Akerele, T., Bailey, C., Brand, C., Chakravarthy, U., Crabb, D. P., Denniston, A., Downey, L., Egan, C., Fitt, A., Johnston, R., Khan, R., Kumar, V., Lee, A., Lobo, A., Mahmood, S., Mandal, K., McKibbin, M., Menon, G., Mitry, D., Natha, S., Sim, D., Tsaloumas, M., Tufail, A., Varma, A., Wilkinson, E., Zhu, H.   +25 more
core   +1 more source